Catherine Dahan-Picard

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Serological diagnosis of chronic skin granulomas caused by wild-type or vaccine-derived rubella virus in patients with inherited HLA class I deficiency.

Serological diagnosis of chronic skin granulomas caused by wild-type or vaccine-derived rubella virus in patients with inherited HLA class I deficiency.

Journal: Journal of human immunity
Published: January 14, 2026

Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trial.

Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trial.

Journal: The British journal of dermatology
Published: December 02, 2025

French national protocol for diagnosis and management of pemphigoid gestationis.

French national protocol for diagnosis and management of pemphigoid gestationis.

Journal: Annales de dermatologie et de venereologie
Published: November 05, 2025

Incidence and mortality of mucous membrane pemphigoid in France.

Incidence and mortality of mucous membrane pemphigoid in France.

Journal: The British journal of dermatology
Published: September 28, 2025

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.

Journal: JAMA dermatology
Published: March 05, 2025

Prevalence of sleep disorders in patients with bullous pemphigoid.

Prevalence of sleep disorders in patients with bullous pemphigoid.

Journal: Annales de dermatologie et de venereologie
Published: December 23, 2024

Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.

Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.

Journal: JAMA dermatology
Published: January 24, 2024

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.

Journal: The British journal of dermatology
Published: May 17, 2023

Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.

Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.

Journal: The British journal of dermatology
Published: February 05, 2023

New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus.

New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus.

Journal: Journal of the American Academy of Dermatology
Published: May 31, 2020

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.

Journal: JAMA dermatology
Published: March 19, 2020

Belimumab for refractory manifestations of cutaneous lupus: A multicenter, retrospective observational study of 16 patients.

Belimumab for refractory manifestations of cutaneous lupus: A multicenter, retrospective observational study of 16 patients.

Journal: Journal of the American Academy of Dermatology
Published: January 01, 2020
Showing 1-12 of 21

Last Updated: 09/26/2026